Which has preferable valuation and earnings, IVA or WHWK?

Whitehawk Therapeutics has higher revenue and earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inventiva $5.07M 157.73 -$400.67M N/A N/A Whitehawk Therapeutics $7.14M 28.81 -$20.60M -$1.68 N/A

Is IVA or WHWK more profitable?

Inventiva's return on equity of 0.00% beat Whitehawk Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Inventiva N/A N/A N/A Whitehawk Therapeutics N/A -79.63% -74.01%

Does the media favor IVA or WHWK?

In the previous week, Inventiva had 1 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 4 mentions for Inventiva and 3 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 1.16 beat Inventiva's score of 0.79 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inventiva 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Whitehawk Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is WHWK or SANA more profitable?

Whitehawk Therapeutics' return on equity of -79.63% beat Sana Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Whitehawk Therapeutics N/A -79.63% -74.01% Sana Biotechnology N/A -108.01% -40.68%

Does the media refer more to WHWK or SANA?

In the previous week, Sana Biotechnology had 1 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 4 mentions for Sana Biotechnology and 3 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 1.16 beat Sana Biotechnology's score of 0.31 indicating that Whitehawk Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Whitehawk Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sana Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer PHAT or WHWK?

In the previous week, Phathom Pharmaceuticals had 2 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 5 mentions for Phathom Pharmaceuticals and 3 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 1.16 beat Phathom Pharmaceuticals' score of 0.37 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phathom Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Whitehawk Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ORIC or WHWK more profitable?

Oric Pharmaceuticals' return on equity of -35.33% beat Whitehawk Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Oric Pharmaceuticals N/A -35.33% -33.31% Whitehawk Therapeutics N/A -79.63% -74.01%

Does the media prefer ORIC or WHWK?

In the previous week, Oric Pharmaceuticals had 3 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 6 mentions for Oric Pharmaceuticals and 3 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 1.16 beat Oric Pharmaceuticals' score of 0.59 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oric Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Whitehawk Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ANNX or WHWK more profitable?

Whitehawk Therapeutics' return on equity of -79.63% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets Annexon N/A -101.19% -75.99% Whitehawk Therapeutics N/A -79.63% -74.01%

Does the media prefer ANNX or WHWK?

In the previous week, Annexon had 2 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 5 mentions for Annexon and 3 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 1.16 beat Annexon's score of 0.97 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annexon 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Whitehawk Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Whitehawk Therapeutics (WHWK) Competitors

$4.16 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$4.16 0.00 (0.00%)

As of 06/12/2026 04:10 PM Eastern

Compare

WHWK vs. IVA, SANA, PHAT, ORIC, and ANNX

Should you buy Whitehawk Therapeutics stock or one of its competitors? MarketBeat compares Whitehawk Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Whitehawk Therapeutics include Inventiva (IVA), Sana Biotechnology (SANA), Phathom Pharmaceuticals (PHAT), Oric Pharmaceuticals (ORIC), and Annexon (ANNX). These companies are all part of the "pharmaceutical products" industry.

How does Whitehawk Therapeutics compare to Inventiva?

Inventiva (NASDAQ:IVA) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

Inventiva currently has a consensus target price of $16.56, suggesting a potential upside of 330.01%. Whitehawk Therapeutics has a consensus target price of $7.33, suggesting a potential upside of 76.28%. Given Inventiva's stronger consensus rating and higher probable upside, analysts plainly believe Inventiva is more favorable than Whitehawk Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inventiva	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Inventiva has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market. Comparatively, Whitehawk Therapeutics has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market.

In the previous week, Inventiva had 1 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 4 mentions for Inventiva and 3 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 1.16 beat Inventiva's score of 0.79 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inventiva	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Whitehawk Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Whitehawk Therapeutics has higher revenue and earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inventiva	$5.07M	157.73	-$400.67M	N/A	N/A
Whitehawk Therapeutics	$7.14M	28.81	-$20.60M	-$1.68	N/A

19.1% of Inventiva shares are owned by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are owned by institutional investors. 32.0% of Inventiva shares are owned by company insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Inventiva's return on equity of 0.00% beat Whitehawk Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inventiva	N/A	N/A	N/A
Whitehawk Therapeutics	N/A	-79.63%	-74.01%

Summary

Inventiva beats Whitehawk Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Whitehawk Therapeutics compare to Sana Biotechnology?

Whitehawk Therapeutics (NASDAQ:WHWK) and Sana Biotechnology (NASDAQ:SANA) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

52.1% of Whitehawk Therapeutics shares are owned by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are owned by institutional investors. 49.9% of Whitehawk Therapeutics shares are owned by company insiders. Comparatively, 25.4% of Sana Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Whitehawk Therapeutics has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market. Comparatively, Sana Biotechnology has a beta of 2.14, suggesting that its stock price is 114% more volatile than the broader market.

Whitehawk Therapeutics has higher revenue and earnings than Sana Biotechnology. Sana Biotechnology is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Whitehawk Therapeutics	$7.14M	28.81	-$20.60M	-$1.68	N/A
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A

Whitehawk Therapeutics' return on equity of -79.63% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Whitehawk Therapeutics	N/A	-79.63%	-74.01%
Sana Biotechnology	N/A	-108.01%	-40.68%

In the previous week, Sana Biotechnology had 1 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 4 mentions for Sana Biotechnology and 3 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 1.16 beat Sana Biotechnology's score of 0.31 indicating that Whitehawk Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Whitehawk Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sana Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Whitehawk Therapeutics presently has a consensus price target of $7.33, suggesting a potential upside of 76.28%. Sana Biotechnology has a consensus price target of $9.50, suggesting a potential upside of 254.48%. Given Sana Biotechnology's stronger consensus rating and higher possible upside, analysts plainly believe Sana Biotechnology is more favorable than Whitehawk Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Sana Biotechnology beats Whitehawk Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Whitehawk Therapeutics compare to Phathom Pharmaceuticals?

Phathom Pharmaceuticals (NASDAQ:PHAT) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings, media sentiment and risk.

Whitehawk Therapeutics has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -76.77%. Phathom Pharmaceuticals' return on equity of 0.00% beat Whitehawk Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phathom Pharmaceuticals	-76.77%	N/A	-44.29%
Whitehawk Therapeutics	N/A	-79.63%	-74.01%

In the previous week, Phathom Pharmaceuticals had 2 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 5 mentions for Phathom Pharmaceuticals and 3 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 1.16 beat Phathom Pharmaceuticals' score of 0.37 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phathom Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Whitehawk Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Phathom Pharmaceuticals presently has a consensus target price of $24.50, suggesting a potential upside of 136.26%. Whitehawk Therapeutics has a consensus target price of $7.33, suggesting a potential upside of 76.28%. Given Phathom Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Phathom Pharmaceuticals is more favorable than Whitehawk Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Whitehawk Therapeutics has lower revenue, but higher earnings than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phathom Pharmaceuticals	$175.11M	4.72	-$221.25M	-$2.12	N/A
Whitehawk Therapeutics	$7.14M	28.81	-$20.60M	-$1.68	N/A

99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are owned by institutional investors. 9.3% of Phathom Pharmaceuticals shares are owned by company insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Phathom Pharmaceuticals has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market. Comparatively, Whitehawk Therapeutics has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market.

Summary

Phathom Pharmaceuticals beats Whitehawk Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Whitehawk Therapeutics compare to Oric Pharmaceuticals?

Oric Pharmaceuticals (NASDAQ:ORIC) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

In the previous week, Oric Pharmaceuticals had 3 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 6 mentions for Oric Pharmaceuticals and 3 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 1.16 beat Oric Pharmaceuticals' score of 0.59 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oric Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Whitehawk Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

95.1% of Oric Pharmaceuticals shares are owned by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are owned by institutional investors. 5.7% of Oric Pharmaceuticals shares are owned by insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Oric Pharmaceuticals has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market. Comparatively, Whitehawk Therapeutics has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market.

Oric Pharmaceuticals currently has a consensus price target of $18.92, suggesting a potential upside of 128.74%. Whitehawk Therapeutics has a consensus price target of $7.33, suggesting a potential upside of 76.28%. Given Oric Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Oric Pharmaceuticals is more favorable than Whitehawk Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Whitehawk Therapeutics has higher revenue and earnings than Oric Pharmaceuticals. Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A
Whitehawk Therapeutics	$7.14M	28.81	-$20.60M	-$1.68	N/A

Oric Pharmaceuticals' return on equity of -35.33% beat Whitehawk Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.33%	-33.31%
Whitehawk Therapeutics	N/A	-79.63%	-74.01%

Summary

Oric Pharmaceuticals beats Whitehawk Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Whitehawk Therapeutics compare to Annexon?

Annexon (NASDAQ:ANNX) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.

Annexon currently has a consensus price target of $16.00, indicating a potential upside of 239.70%. Whitehawk Therapeutics has a consensus price target of $7.33, indicating a potential upside of 76.28%. Given Annexon's higher probable upside, analysts clearly believe Annexon is more favorable than Whitehawk Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annexon	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Whitehawk Therapeutics has higher revenue and earnings than Annexon. Annexon is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annexon	N/A	N/A	-$206.69M	-$1.22	N/A
Whitehawk Therapeutics	$7.14M	28.81	-$20.60M	-$1.68	N/A

52.1% of Whitehawk Therapeutics shares are owned by institutional investors. 10.3% of Annexon shares are owned by company insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Annexon has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market. Comparatively, Whitehawk Therapeutics has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market.

Whitehawk Therapeutics' return on equity of -79.63% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annexon	N/A	-101.19%	-75.99%
Whitehawk Therapeutics	N/A	-79.63%	-74.01%

In the previous week, Annexon had 2 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 5 mentions for Annexon and 3 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 1.16 beat Annexon's score of 0.97 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annexon	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Whitehawk Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Whitehawk Therapeutics beats Annexon on 9 of the 13 factors compared between the two stocks.

Get Whitehawk Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WHWK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

WHWK vs. The Competition

Export

Metric	Whitehawk Therapeutics	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$205.71M	$759.83M	$4.91B	$12.07B
Dividend Yield	N/A	4.84%	10.25%	5.67%
P/E Ratio	-2.48	1.45	22.22	24.42
Price / Sales	28.81	120.48	159.46	109.94
Price / Cash	N/A	20.06	40.19	37.92
Price / Book	1.44	7.85	26.92	6.83
Net Income	-$20.60M	-$4.88M	$116.61M	$337.67M
7 Day Performance	3.48%	0.64%	0.25%	1.17%
1 Month Performance	-11.49%	-0.16%	0.25%	3.16%
1 Year Performance	N/A	47.51%	14.23%	30.58%

Whitehawk Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
WHWK Whitehawk Therapeutics	3.874 of 5 stars	$4.16 flat	$7.33 +76.3%	N/A	$205.71M	$7.14M	N/A	21
IVA Inventiva	2.7663 of 5 stars	$3.80 +0.5%	$16.56 +335.7%	+12.9%	$785.13M	$5.07M	N/A	100
SANA Sana Biotechnology	2.1943 of 5 stars	$2.77 -1.8%	$9.50 +243.0%	+3.5%	$784.78M	N/A	N/A	380
PHAT Phathom Pharmaceuticals	2.4706 of 5 stars	$10.27 +4.6%	$24.50 +138.6%	-2.5%	$783.20M	$175.11M	N/A	110
ORIC Oric Pharmaceuticals	2.6179 of 5 stars	$7.82 +3.7%	$19.36 +147.6%	-14.1%	$780.52M	N/A	N/A	80	Analyst Forecast Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:WHWK) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Whitehawk Therapeutics (WHWK) Competitors

WHWK vs. IVA, SANA, PHAT, ORIC, and ANNX

How does Whitehawk Therapeutics compare to Inventiva?

Summary

How does Whitehawk Therapeutics compare to Sana Biotechnology?

Summary

How does Whitehawk Therapeutics compare to Phathom Pharmaceuticals?

Summary

How does Whitehawk Therapeutics compare to Oric Pharmaceuticals?

Summary

How does Whitehawk Therapeutics compare to Annexon?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WHWK vs. The Competition

Whitehawk Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Whitehawk Therapeutics (WHWK) Competitors

WHWK vs. IVA, SANA, PHAT, ORIC, and ANNX

How does Whitehawk Therapeutics compare to Inventiva?

Do analysts rate IVA or WHWK?

Which has more volatility & risk, IVA or WHWK?

Does the media favor IVA or WHWK?

Which has preferable valuation and earnings, IVA or WHWK?

Do insiders & institutionals hold more shares of IVA or WHWK?

Is IVA or WHWK more profitable?

Summary

How does Whitehawk Therapeutics compare to Sana Biotechnology?

Do institutionals and insiders hold more shares of WHWK or SANA?

Which has more risk & volatility, WHWK or SANA?

Which has better valuation and earnings, WHWK or SANA?

Is WHWK or SANA more profitable?

Does the media refer more to WHWK or SANA?

Do analysts recommend WHWK or SANA?

Summary

How does Whitehawk Therapeutics compare to Phathom Pharmaceuticals?

Is PHAT or WHWK more profitable?

Does the media prefer PHAT or WHWK?

Do analysts rate PHAT or WHWK?

Which has preferable valuation & earnings, PHAT or WHWK?

Do institutionals & insiders have more ownership in PHAT or WHWK?

Which has more risk & volatility, PHAT or WHWK?

Summary

How does Whitehawk Therapeutics compare to Oric Pharmaceuticals?

Does the media prefer ORIC or WHWK?

Do institutionals and insiders have more ownership in ORIC or WHWK?

Which has more risk and volatility, ORIC or WHWK?

Do analysts rate ORIC or WHWK?

Which has stronger earnings and valuation, ORIC or WHWK?

Is ORIC or WHWK more profitable?

Summary

How does Whitehawk Therapeutics compare to Annexon?

Do analysts prefer ANNX or WHWK?

Which has stronger valuation & earnings, ANNX or WHWK?

Do insiders and institutionals have more ownership in ANNX or WHWK?

Which has more volatility & risk, ANNX or WHWK?

Is ANNX or WHWK more profitable?

Does the media prefer ANNX or WHWK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WHWK vs. The Competition

Whitehawk Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools